UK wellness products firm Cellular Goods has filed its first patent application related to the use of cannabinoids for skin brightening.
‘Dermal Composition Comprising Cannabinoid and Derivatives Thereof’, filed on 26 April with the UK Intellectual Property Office, is anticipated to form part of a wider patent portfolio driven by Cellular Goods’ research into the wellness benefits of lab-made cannabinoids.
Cellular Goods’ in vitro research found cannabigerol (CBG) can improve the effectiveness of certain active ingredients used in traditional skin brightening products.
These findings provide the basis for a new class of skin brightening solutions that can improve skin tone evenness associated with melasma and hyperpigmentation.
Cellular Goods offers Rejuvenating Cannabinoid Face Serum, the UK’s first CBG-based serum to prevent the signs of aging caused by UV light exposure and inflammation.
“The filing of this patent based on our own research is part of our efforts to help unveil the benefits of cannabinoids, as well as to develop science-backed innovations that can improve people’s wellness,” said Cellular Goods chief executive Anna Chokina.
“We look forward to contributing to the growing body of research on cannabinoids, particularly their skincare benefits, while also growing our patent portfolio,” she added.
R&D head Alexia Blake added: “We are committed to continuing to develop research that will help us better understand the unique benefits of cannabinoids and how to effectively leverage these benefits across our product offerings.”
In a related development, a new variety of hemp seed containing high levels of CBG developed by Italian-Dutch company Enecta has been added to the EU Common Catalogue.
Blue Label status allows standardisation of the hemp seeds – known as Enectarol - and to freely sell them in the EU regulated market and allows growers to apply for Community Agricultural Policy funding.
